Press release
Chronic Hepatitis B Virus Treatment Pipeline Shows Strong Momentum as 50+ Pharma Companies in the Race | DelveInsight
Discover the latest drugs and treatment options in the Chronic Hepatitis B Virus Pipeline @ Chronic Hepatitis B Virus Pipeline Outlook [https://www.delveinsight.com/sample-request/chronic-hepatitis-b-virus-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Chronic Hepatitis B Virus Pipeline Report
* On March 02, 2026- Gilead Sciences initiated a clinical study are to compare the effectiveness, safety and tolerability of study drug, tenofovir alafenamide (TAF), versus placebo in teens and children with CHB and to learn more about the dosing levels in children.
* In February 2026- Aligos Therapeutics announced a Phase 2 study to evaluate the efficacy and safety of 48 weeks of oral (PO) once daily (QD) monotherapy with ALG-000184 versus TDF in treatment naive (TN) or currently not treated (CNT) HBeAg-positive and HBeAg-negative subjects with chronic HBV infection (inclusive of chronic infection and/or chronic hepatitis).
* In February 2026- GlaxoSmithKline conducted a study will evaluate the efficacy and safety of bepirovirsen compared to placebo in participants with human immunodeficiency virus (HIV)/hepatitis B virus (HBV) co-infection.
* In February 2026- Vir Biotechnology Inc. initiated a Phase 1b/2 platform study framework to evaluate the safety and efficacy of investigational candidate(s) and their combinations as potential treatments for adults with chronic hepatitis B virus infection.
* DelveInsight's Chronic Hepatitis B Virus pipeline report depicts a robust space with 50+ active players working to develop 55+ pipeline therapies for Chronic Hepatitis B Virus treatment.
* The leading Chronic Hepatitis B Virus Companies such as Vedanta Biosciences, Gilead Sciences, Dong-A ST Co, Assembly Biosciences, Arbutus Biopharma, Vir Biotechnology, Antios Therapeutics, Ascletis Pharmaceuticals, Shanghai HEP Pharmaceutical, Romark Laboratories, Qilu Pharmaceutical, Golden Biotechnology, Sunshine Lake Pharma, Ascentage Pharma, GlaxoSmithKline, Janssen Sciences, Henlix, Enyo Pharma, Tasly Tianjin Biopharmaceutical, Brii Biosciences, Vaxine Pty Ltd, Vaccitech Limited, Zhejiang Palo Alto Pharmaceuticals, Suzhou Ribo Life Science, PharmaEssentia, Nucorion Pharmaceuticals, Jiangsu HengRui Medicine, Enanta Pharmaceuticals, Chong Kun Dang Pharmaceutical, Guangzhou Lupeng Pharmaceutical, VenatoRx Pharmaceuticals, Zhimeng Biopharm . And others.
* Promising Chronic Hepatitis B Virus Pipeline Therapies such as Peginterferon Alfacon, Daplusiran/Tomligisiran Dose Level 1, Bepirovirsen, Tenofovir disoproxil fumarate (TDF), VIR-2218, PEG-IFN, and others.
Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Chronic Hepatitis B Virus Treatment Drugs [https://www.delveinsight.com/sample-request/chronic-hepatitis-b-virus-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Chronic Hepatitis B Virus Emerging Drugs Profile
* Pradefovir: Ligand Pharmaceuticals
Pradefovir is an oral liver-targeting prodrug of the HBV DNA polymerase/reverse transcriptase inhibitor adefovir, for the potential treatment of hepatitis B virus (HBV) infection. The drug is developing using Ligand's HepDirect technology. Currently the product is in Phase III stage of development for the treatment of Chronic Hepatitis B.
* RG6346: Dicerna Pharmaceuticals
RG6346 is an investigational GalXC Trademark RNAi therapeutic candidate in development in collaboration with Roche for the treatment of chronic HBV infection. RG6346 is designed to employ RNA interference to selectively knock down specific genes involved in the creation of HBV messenger RNA (mRNA) and the entry of the virus into liver cells. Preclinical data have demonstrated greater than 99.9% reduction in circulating HBsAg, as observed in mouse models of HBV infection. Unlike current therapies that typically provide long-term suppression of the virus, RG6346 has the potential to provide a functional cure for patients living with chronic HBV. Dicerna is currently conducting a Phase II trial of RG6346 in adult patients with chronic HBV infection.
The Chronic Hepatitis B Virus Pipeline Report Provides Insights into
* The report provides detailed insights about companies that are developing therapies for the treatment of Chronic Hepatitis B Virus with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Chronic Hepatitis B Virus Treatment.
* Chronic Hepatitis B Virus Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Chronic Hepatitis B Virus Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Chronic Hepatitis B Virus market
Explore groundbreaking therapies and clinical trials in the Chronic Hepatitis B Virus Pipeline @ New Chronic Hepatitis B Virus Drugs [https://www.delveinsight.com/sample-request/chronic-hepatitis-b-virus-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Chronic Hepatitis B Virus Companies
Vedanta Biosciences, Gilead Sciences, Dong-A ST Co, Assembly Biosciences, Arbutus Biopharma, Vir Biotechnology, Antios Therapeutics, Ascletis Pharmaceuticals, Shanghai HEP Pharmaceutical, Romark Laboratories, Qilu Pharmaceutical, Golden Biotechnology, Sunshine Lake Pharma, Ascentage Pharma, GlaxoSmithKline, Janssen Sciences, Henlix, Enyo Pharma, Tasly Tianjin Biopharmaceutical, Brii Biosciences, Vaxine Pty Ltd, Vaccitech Limited, Zhejiang Palo Alto Pharmaceuticals, Suzhou Ribo Life Science, PharmaEssentia, Nucorion Pharmaceuticals, Jiangsu HengRui Medicine, Enanta Pharmaceuticals, Chong Kun Dang Pharmaceutical, Guangzhou Lupeng Pharmaceutical, VenatoRx Pharmaceuticals, Zhimeng Biopharm and others.
Chronic Hepatitis B Virus Infection pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Oral
* Parenteral
* Intravenous
* Subcutaneous
* Topical
Chronic Hepatitis B Virus Products have been categorized under various Molecule types such as
* Monoclonal Antibody
* Peptides
* Polymer
* Small molecule
* Gene therapy
Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Chronic Hepatitis B Virus Market Drivers and Barriers [https://www.delveinsight.com/sample-request/chronic-hepatitis-b-virus-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Chronic Hepatitis B Virus Pipeline Report
* Coverage- Global
* Chronic Hepatitis B Virus Companies- Vedanta Biosciences, Gilead Sciences, Dong-A ST Co, Assembly Biosciences, Arbutus Biopharma, Vir Biotechnology, Antios Therapeutics, Ascletis Pharmaceuticals, Shanghai HEP Pharmaceutical, Romark Laboratories, Qilu Pharmaceutical, Golden Biotechnology, Sunshine Lake Pharma, Ascentage Pharma, GlaxoSmithKline, Janssen Sciences, Henlix, Enyo Pharma, Tasly Tianjin Biopharmaceutical, Brii Biosciences, Vaxine Pty Ltd, Vaccitech Limited, Zhejiang Palo Alto Pharmaceuticals, Suzhou Ribo Life Science, PharmaEssentia, Nucorion Pharmaceuticals, Jiangsu HengRui Medicine, Enanta Pharmaceuticals, Chong Kun Dang Pharmaceutical, Guangzhou Lupeng Pharmaceutical, VenatoRx Pharmaceuticals, Zhimeng Biopharm . And others.
* Chronic Hepatitis B Virus Pipeline Therapies- Peginterferon Alfacon, Daplusiran/Tomligisiran Dose Level 1, Bepirovirsen, Tenofovir disoproxil fumarate (TDF), VIR-2218, PEG-IFN, and others.
* Chronic Hepatitis B Virus Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Chronic Hepatitis B Virus Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Download DelveInsight's in-depth pipeline report today! @ Chronic Hepatitis B Virus Companies, Key Products and Unmet Needs [https://www.delveinsight.com/sample-request/chronic-hepatitis-b-virus-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
* Introduction
* Executive Summary
* Chronic Hepatitis B Virus Infection: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Chronic Hepatitis B Virus Infection - DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Pradefovir: Ligand Pharmaceuticals
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* RG6346: Dicerna Pharmaceuticals
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I/II)
* Drug name: Company name
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* VIR-3434: Vir Biotechnology
* Drug profiles in the detailed report.....
* Preclinical Stage Products
* SBT8230: Silverback Therapeutics
* Drug profiles in the detailed report.....
* Inactive Products
* Chronic Hepatitis B Virus Infection Key Companies
* Chronic Hepatitis B Virus Infection Key Products
* Chronic Hepatitis B Virus Infection - Unmet Needs
* Chronic Hepatitis B Virus Infection - Market Drivers and Barriers
* Chronic Hepatitis B Virus Infection - Future Perspectives and Conclusion
* Chronic Hepatitis B Virus Infection Analyst Views
* Chronic Hepatitis B Virus Infection Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=chronic-hepatitis-b-virus-treatment-pipeline-shows-strong-momentum-as-50-pharma-companies-in-the-race-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/chronic-hepatitis-b-virus-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Chronic Hepatitis B Virus Treatment Pipeline Shows Strong Momentum as 50+ Pharma Companies in the Race | DelveInsight here
News-ID: 4421170 • Views: …
More Releases from ABNewswire
Autosomal Dominant Polycystic Kidney Disease Market Set for Robust Growth by 203 …
The dynamics of the autosomal dominant polycystic kidney disease market are anticipated to change in the coming years, owing to the launch of emerging therapies such as XRx-008 (Xortx Therapeutics), CYX082 (Novartis), AZD1613 (AstraZeneca), VX-407 (Vertex Pharmaceuticals), ABBV-CLS-628 (Calico Life Sciences/AbbVie), and others and increasing cases of ADPKD during the forecast period (2025-2034).
Recently published Autosomal Dominant Polycystic Kidney Disease Market Insights report includes a comprehensive understanding of current treatment practices,…
CT-388 Comprehensive Forecast on the Accelerating Market Growth for Obesity and …
[Las Vegas, United States] DelveInsight, a leader in healthcare research firm, has recently published an in-depth report on CT-388 providing insights into the drug market landscape and market forecast of CT-388 upto 2034.
Are you interested in finding out the projected market size of CT-388 in 2034? CT-388 Market Forecast [https://www.delveinsight.com/sample-request/ct-388-market-forecast?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Factors Driving CT-388 Growth
1. Market Share Gains and New Patient Starts
* CT-388 is still in clinical development, so it has…
Chronic Lymphocytic Leukemia Clinical Trial Pipeline Appears Robust With 55+ Key …
DelveInsight's, "Chronic Lymphocytic Leukemia Pipeline Insight 2026" report provides comprehensive insights about 55+ companies and 60+ pipeline drugs in Chronic Lymphocytic Leukemia (CLL) pipeline landscape. It covers the Chronic Lymphocytic Leukemia pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Chronic Lymphocytic Leukemia pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Download…
Cholangiocarcinoma Clinical Trial Pipeline Shows Potential with Active Contribut …
DelveInsight's, "Cholangiocarcinoma Pipeline Insight 2026" report provides comprehensive insights about 55+ companies and 60+ pipeline drugs in Cholangiocarcinoma pipeline landscape. It covers the Cholangiocarcinoma Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Cholangiocarcinoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight and stay ahead in…
More Releases for Vir
Influenza A Market: Epidemiology, Therapies, Companies, DelveInsight | Cidara Th …
The influenza A market report provides current treatment practices, emerging drugs, market share of individual therapies, and current and forecasted 7MM influenza A market size from 2020 to 2034. The report also covers current influenza A treatment practices/algorithms and unmet medical needs to curate the best opportunities and assess the market's potential.
Influenza A therapies, such as XOFLUZA, RAPIVAB, FLUAD QUADRIVALENT, mRNA-1010, CD388, Flu Pandemic mRNA (GSK4382276A), CC-42344, and others, are…
Influenza A Market: Epidemiology, Therapies, Companies, DelveInsight | Cidara Th …
Influenza A therapies, such as XOFLUZA, RAPIVAB, FLUAD QUADRIVALENT, mRNA-1010, CD388, Flu Pandemic mRNA (GSK4382276A), CC-42344, and others, are expected to boost the Influenza A Market in the upcoming years.
DelveInsight has launched a new report on "Influenza A - Market Insights, Epidemiology, and Market Forecast-2034" that delivers an in-depth understanding of the Influenza A, historical and forecasted epidemiology as well as the Influenza A market trends in the United States,…
Investigation for NASDAQ: VIR Investors over possible Wrongdoing at Vir Biotechn …
An investigation was announced over potential breaches of fiduciary duties by certain directors at Vir Biotechnology, Inc.
Investors who purchased shares of Vir Biotechnology, Inc. (NASDAQ: VIR) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm concerns whether certain Vir Biotechnology directors breached their fiduciary duties and caused damage to the company and its shareholders.
San Francisco, CA based…
SOFTWARE-DEFINED NETWORKING AND NETWORK FUTUALIZATION MARKET knowNCTION VIR indu …
“The SDN and NFV is picking up noticeable quality because of the developing mechanical progressions in systems administration and server farm union. SDN is a momentous systems administration design, which is ready to totally alter the current systems administration and server farm foundation. The SDN building structure is set to reclassify the systems administration framework to meet the developing number of system clients devouring a high data transfer capacity. With…
Investigation announced for Investors in shares of Vir Biotechnology, Inc. (NASD …
Vir Biotechnology, Inc is under investigation concerning potential securities laws violations in connection with certain financial statements.
Investors who purchased shares of Vir Biotechnology, Inc. (NASDAQ: VIR), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm focuses on whether a series of statements by Vir Biotechnology, Inc. regarding its business, its prospects and its operations were materially false…
Global Balancing Valves Market 2017 - IMI Hydronic, Danfoss, Frese A/S, Caleffi, …
"A balancing valve is a measurement and regulation device. Balancing valves are used in pressurized piping applications, such as HVAC and gas movement applications. The main purpose of a balancing valve is generally to create a consistent output pressure to a system from an inconsistent input pressure from a different system."
Scope of the Report:
This report focuses on the Balancing Valves in Global market, especially in North America, Europe and Asia-Pacific,…
